NovaRx Corporation
Quick facts
Phase 3 pipeline
- Lucanix™ · Oncology
Lucanix is a dendritic cell-based cancer vaccine that activates the immune system to recognize and attack tumor cells expressing PRAME antigen.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about NovaRx Corporation
What is NovaRx Corporation's pipeline?
NovaRx Corporation has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Lucanix™.
Related
- Sector hub: All tracked pharma companies